2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2653

Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2403

Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 1957

Aggregation of Functional Variants in NOTCH4 Gene Increases SSc Risk

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2723

Alagille Syndrome and Chronic Arthritis: An International Case Series

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2069

Alcohol Consumption Is Not an Independent Predictor of Fatigue Severity over Time

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 1984

Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model but Not in A2A KO Mice

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2416

ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2419

An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2096

An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2542

An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 1939

Analysis of Discoid Lupus Erythematosus (DLE) Gene Expression Reveals Dysregulation of Pathogenic Pathways Associated with Infiltrating Immune/Inflammatory Cells

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2022

Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1930

Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2634

ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2642

ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA

Vasculitis – ANCA-Associated Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].